ESR1 and breast cancer: In another proof-of-concept study breast cancer organoids were derived from one patient and drug screening identified fulvestrant (estrogen receptor antagonist) as the most optimal treatment for this patient whereas based on genetic analysis (PTEN mutant), everolimus was expected to be the most effective treatment.